Komori
General Meetings of Shareholders4884Kringle Pharma,Inc.Pharmaceuticals

Notice of Convocation of an Extraordinary General Meeting of Shareholders

At the extraordinary general meeting of shareholders, a proposal was submitted to reduce stated capital and capital reserves, transfer the reductions to other capital surplus, and then transfer that surplus to retained earnings brought forward to eliminate the deficit. The total number of issued shares, net assets, the number of shares held by shareholders, and net assets per share will remain unchanged.

Worth reading
51Recurring
Scored from 3 of 4 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
331330050
Yen (amount of stated capital to be reduced)
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Extraordinary General Meeting of Shareholders
2026
Aug 28
Date and time(Friday), 3:30 p.m. (受付開始 3:00 p.m.)22 days from this disclosure to the meeting
Matters for resolution1 item
  1. Reduction of the Amounts of Stated Capital and Capital Reserves and Disposition of Surplus

Shareholder Proposal

No

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingExtraordinary General Meeting of Shareholders
Date and time28 August 2026 (Friday), 3:30 p.m. (受付開始 3:00 p.m.)
Matters for resolutionReduction of the Amounts of Stated Capital and Capital Reserves and Disposition of Surplus
Shareholder ProposalNo
Items this document does not state (2)
Director nomineePercentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To strengthen the financial position, increase flexibility in future capital policies, including shareholder returns, reduce the tax burden, and eliminate the deficit in retained earnings brought forward.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of an Extraordinary General Meeting of Shareholders | Kringle Pharma,Inc. (4884) timely disclosure | Komori